By Primary Care Evidence Guide Editorial Team
If you have diabetes, your A1C number gets most of the attention — but it is not the only number that determines what happens to your heart. Adults with diabetes are nearly twice as likely to have heart disease or stroke as adults without it, and that gap is driven by more than blood glucose alone. Blood pressure, cholesterol, smoking status, kidney function, and family history all feed into the same outcome. Treatment choices that address only A1C can leave real cardiovascular risk unmanaged.
This page walks through what “beyond A1C” means in practice: the other numbers involved, how evidence differs from one medicine to the next, and a decision map for the conversation worth having with your care team.
Why A1C Alone Doesn't Tell the Whole Story
A1C reflects your average blood glucose over roughly three months. It's a genuinely useful marker — for many people with diabetes the goal is below 7% — but that target can shift with age, other health conditions, and how your care team weighs tighter control against the risk of low blood sugar episodes.
What A1C doesn't measure is blood pressure, LDL or HDL cholesterol, smoking status, or whether your kidneys are under strain. High blood glucose over time can damage blood vessels and the nerves that control the heart — that's the direct mechanical link between diabetes and heart disease — but the other risk factors compound on top of it independently. It's possible to be at your A1C goal and still carry substantial, unaddressed cardiovascular risk if blood pressure and cholesterol aren't being managed at the same time.
This is the same gap covered from the metabolic side in our look at why blood sugar control can stall even with diet changes: glucose numbers are one piece of a larger system, not the whole picture.
The Other Numbers: Blood Pressure, Cholesterol, and Smoking
Diabetes care organized around the “ABCs” treats A1C as one of several targets, not the only one:
- Blood pressure: the general goal for most people with diabetes is below 140/90 mm Hg, though your care team may set a different target for you. Uncontrolled blood pressure makes the heart work harder and raises the risk of heart attack, stroke, and kidney or eye damage.
- Cholesterol: LDL (“bad”) cholesterol can build up in blood vessels and raise heart disease risk; higher HDL (“good”) cholesterol is linked to lower risk. People with diabetes over 40 are often candidates for a statin to protect against heart attack and stroke — ask your care team what your specific numbers and goals should be.
- Smoking: smoking and diabetes both narrow blood vessels, so the combination compounds risk more than either alone. Quitting is one of the few single interventions shown to lower heart attack, stroke, and amputation risk.
Excess weight around the waist, chronic kidney disease — which affects an estimated 40% of people with diabetes and is closely linked to heart disease — and a family history of early heart disease add further to the picture. None of these show up on an A1C result alone.
Which Evidence Applies to a Particular Medicine
This is where “beyond A1C” gets practical, and where a one-size-fits-all answer stops being honest. Not every medicine that lowers glucose has the same kind of evidence behind it, and the distinctions matter:
- Glucose-lowering medicines generally are evaluated primarily on how well they bring A1C down and keep it stable.
- Certain diabetes medicines have additionally been shown in clinical trials to reduce the risk of heart attack and death specifically in patients already at very high cardiovascular risk. That's a separate finding from glucose control, and it doesn't apply uniformly to everyone with diabetes.
- Statins are evaluated on cardiovascular outcomes directly — reducing heart attack and stroke risk — which is a distinct question from blood glucose management.
In practice, a medicine can be excellent at lowering A1C without carrying cardiovascular-outcome evidence, and a medicine can carry strong cardiovascular-outcome evidence without being a first-line glucose drug. Whether a specific medicine's evidence applies to you depends on which risk category you're actually in — something only your prescribing clinician can determine from your full history and labs, not something a general article can settle.
A Decision Map for This Conversation
Rather than a generic checklist, here's how to work through this specific question — diabetes and heart disease treatment — in a way that maps to what your care team actually needs to see.
Terms worth defining before the conversation
- A1C goal — the target your clinician has set for you, and whether it's the standard sub-7% goal or adjusted for your situation
- Cardiovascular risk category — whether you've been told you're at elevated or very high risk, since this changes which medicines have applicable trial evidence
- Renal function stage — your eGFR or kidney function status, since several heart-protective diabetes medicines carry different guidance depending on kidney function
- Outcome indication — what a given medicine's trial evidence actually demonstrated (glucose control, heart attack reduction, heart failure reduction, kidney protection) versus what it's being prescribed for
Evidence or records to bring to the appointment
- Your most recent A1C, blood pressure, and lipid panel results — together, not just one
- Current kidney function labs (eGFR, creatinine), since this affects which medicines are appropriate and at what dose
- A current medication list, including supplements, so interactions can be checked before anything new is added
- Family cardiovascular history — specifically whether a parent or sibling had a heart attack before age 50
- Smoking status and any prior quit attempts
Meaningful limits and safety boundaries
- Cardiovascular-outcome evidence for specific diabetes medicines generally applies to people